Drug Profile
Smoking cessation oral spray - Emphycorp
Latest Information Update: 04 Oct 2019
Price :
$50
*
At a glance
- Originator Emphycorp
- Developer Emphycorp; Unknown
- Class Smoking cessation therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Smoking withdrawal
Most Recent Events
- 04 Oct 2019 Smoking cessation oral spray is still in phase I/II trials for Smoking withdrawal in USA (Emphycorp website, September 2019)